Benlysta* (Belimumab) — Medicare Part D spending
Glaxosmithkline* · Rank #237 by total Part D spend · CMS data year 2023
Medicare Part D spent $187,011,628 on Benlysta* (Belimumab) in 2023, the #237 drug by total Part D spending out of 3,598 drugs. That worked out to about $1,241.82 per dosage unit, $4,843 per claim and $37,872 per beneficiary, across 38,613 claims for 4,938 beneficiaries. Average spending per dosage unit rose +14.8% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Benlysta* (Belimumab) spending at a glance (2023)
| Metric | Benlysta* (Belimumab) |
|---|---|
| Total Part D spending (2023) | $187,011,628 |
| Total spending (2022) | $149,755,010 |
| Year-over-year change in total spending | +24.9% |
| Average spending per dosage unit (2023) | $1,241.82 |
| Change in spend per dosage unit (YoY) | +14.8% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +6.8% |
| Average spending per claim (2023) | $4,843 |
| Average spending per beneficiary (2023) | $37,872 |
| Total claims (2023) | 38,613 |
| Beneficiaries (2023) | 4,938 |
| Total dosage units (2023) | 156,259 |
| Manufacturer(s) | Glaxosmithkline* |
| National rank by total spend (of 3,598 drugs) | #237 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $149,755,010 | $187,011,628 | +24.9% |
| Avg spend per dosage unit | $1,081.91 | $1,241.82 | +14.8% |
| Avg spend per claim | $4,430 | $4,843 | — |
| Avg spend per beneficiary | $34,020 | $37,872 | — |
| Total claims | 33,805 | 38,613 | — |
| Beneficiaries | 4,402 | 4,938 | — |
How Benlysta* compares with nearby drugs
Drugs with total Part D spending closest to Benlysta* (Belimumab):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Benlysta* (Belimumab) (this drug, #237) | $187,011,628 | $1,241.82 | +14.8% |
| Sevelamer Carbonate (#235) | $189,369,170 | $1.20 | -15.2% |
| Vemlidy (Tenofovir Alafenamide) (#236) | $187,858,704 | $48.73 | +7.3% |
| Alecensa (Alectinib HCl) (#238) | $185,955,638 | $77.07 | +6.3% |
| Actemra Actpen (Tocilizumab) (#239) | $184,648,416 | $1,330.09 | +6.8% |
| Tibsovo (IVosidenib) (#240) | $184,488,983 | $549.19 | +6.7% |
Frequently asked questions
How much does Medicare Part D spend on Benlysta*?
Medicare Part D spent $187,011,628 on Benlysta* (Belimumab) in 2023 (the latest CMS data year), across 38,613 claims for 4,938 beneficiaries. That ranks #237 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Benlysta*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Benlysta* (Belimumab) was $1,241.82. Compared with 2022 it rose +14.8%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Benlysta*?
CMS attributes Benlysta* (Belimumab) to Glaxosmithkline* in the 2023 Part D spending file. Average spending per claim was $4,843 and per beneficiary $37,872.
Is the Benlysta* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20